Janux Therapeutics与百时美施贵宝合作提名开发候选药物,触发3500万美元里程碑付款

美股速递
Apr 01

Janux Therapeutics, Inc.宣布,在与百时美施贵宝的合作框架下,已正式提名一项开发候选药物。这一进展触发了合作协议中约定的3500万美元里程碑付款条款。

此次候选药物的提名标志着双方在肿瘤免疫治疗领域的合作取得实质性突破。该里程碑付款的兑现,将进一步支持Janux Therapeutics推进其创新疗法管线的研发进程。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10